Hostname: page-component-89b8bd64d-rbxfs Total loading time: 0 Render date: 2026-05-08T01:18:06.696Z Has data issue: false hasContentIssue false

Curcumin attenuates hepatic fibrosis and insulin resistance induced by bile duct ligation in rats

Published online by Cambridge University Press:  08 June 2018

Azam Eshaghian
Affiliation:
Department of Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, 8915173149, Iran
Ameneh Khodarahmi
Affiliation:
Department of Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, 8915173149, Iran
Fatemeh Safari
Affiliation:
Department of Physiology, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, 8915173149, Iran
Fariba Binesh
Affiliation:
Department of Pathology, Shahid Sadoughi University of Medical Sciences, Yazd, 8915173149, Iran
Ali Moradi*
Affiliation:
Department of Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, 8915173149, Iran
*
*Corresponding author: A. Moradi, email moradi20018@gmail.com
Rights & Permissions [Opens in a new window]

Abstract

Recent studies have strongly indicated the hepatoprotective effect of curcumin; however, the precise mechanisms are not well understood. This study aimed to determine the protective effect of curcumin on hepatic damage and hepatic insulin resistance in biliary duct ligated (BDL) fibrotic rat model. To accomplish this, male Wistar rats were divided into four groups (eight for each): sham group, BDL group, sham+Cur group and BDL+Cur group. The last two groups received curcumin at a dose of 100 mg/kg daily for 4 weeks. The mRNA/protein expression levels of Ras-related C3 botulinum toxin substrate 1 (Rac1), Rac1-GTP, dinucleotide phosphate oxidase 1 (NOX1), signal transducer and activator of transcription 3 (STAT3), suppressor of cytokine signalling 3 (SOCS3), insulin receptor substrate 1 (IRS1), extracellular signal-regulated kinase 1 (ERK1), specific protein 1 (Sp1) and hypoxia-inducible factor-1α (HIF-1α) were measured by real-time PCR and Western blotting, respectively. Fasting blood glucose, insulin and Leptin levels were determined and homoeostasis model assessment-estimated insulin resistance, as an index of insulin resistance, was calculated. Curcumin significantly attenuated liver injury and fibrosis, including amelioration of liver histological changes, reduction of hepatic enzymes, as well as decreased expression of liver fibrogenesis-associated variables, including Rac1, Rac1-GTP, NOX1, ERK1, HIF-1α and Sp1. Curcumin also attenuated leptin level and insulin resistance, which had increased in BDL rats (P<0·05). Furthermore, compared with the BDL group, we observed an increase in IRS1 and a decrease in SOCS3 and STAT3 expression in the curcumin-treated BDL group (P<0·05), indicating return of these parameters towards normalcy. In conclusion, Curcumin showed hepatoprotective activity against BDL-induced liver injury and hepatic insulin resistance by influencing the expression of some genes/proteins involved in these processes, and the results suggest that it can be used as a therapeutic option.

Information

Type
Full Papers
Copyright
© The Authors 2018 
Figure 0

Table 1 Primer sequences used for real-time PCR

Figure 1

Fig. 1 Curcumin treatment reduced bile duct ligation (BDL)-induced liver injury, as shown by histological examination. Representative photomicrographs of haematoxylin–eosin staining showing (a) Sham, (b) Curcumin-treated Sham (Sham+Cur), (c) BDL and (d) Curcumin-treated BDL (BDL+Cur) rat liver sections.

Figure 2

Table 2 Effect of curcumin on liver enzymes (aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP)), total bilirubin (TBIL), direct bilirubin (DBIL), malondialdehyde (MDA) and 2,2-diphenyl-1-picrylhydrazyl (DPPH) in four groups of rats (Mean values and standard deviations)

Figure 3

Table 3 Comparison of α-smooth muscle actin (α-SMA), transforming growth factor β1 (TGF-β1), collagen I, IL-1β, TNF-α, inducible nitric oxide synthase (iNOS) and NF-κB mRNA expression in liver tissue of four groups (Mean values and standard deviations)

Figure 4

Table 4 Effects of curcumin (Cur) on fasting blood glucose (FBG), fasting blood insulin (FBI), homoeostasis model assessment-estimated insulin resistance (HOMA-IR) index and leptin levels in serum of four groups (Mean values and standard deviations)

Figure 5

Fig. 2 Western blotting pattern of Ras-related C3 botulinum toxin substrate 1 (Rac1), Rac1-GTP, dinucleotide phosphate oxidase 1 (NOX1), signal transducer and activator of transcription 3 (STAT3), suppressor of cytokine signalling 3 (SOCS3) and insulin receptor substrate 1 (IRS1) protein expression (a); the relative density of protein expression levels of NOX1, Rac1 and Rac1-GTP, which are involved in ROS generation and liver fibrogenesis, (b) and STAT3, SOCS3 and IRS1, which contribute to insulin resistance (c) in the four studied groups (Sham, Curcumin-treated Sham (Sham+Cur), bile duct ligation (BDL), Curcumin-treated BDL (BDL+ Cur)). Values are means (n 6) and standard deviations represented by vertical bars. * P value<0·05 compared with the Sham group. † P value<0·05 compared with the BDL group. b: , Rac1; , Rac1-GTP; , NOX1; c: , STAT3; , SOCS3; , IRS1.

Figure 6

Fig. 3 Gene expression of extracellular signal-regulated kinase 1 (ERK1) (a), hypoxia-inducible factor-1α (HIF-1α) (b), specific protein 1 (Sp1) (c), signal transducer and activator of transcription 3 (STAT3) (d), suppressor of cytokine signalling 3 (SOCS3) (e) and insulin receptor substrate 1 (IRS1) (f) in the four studied groups (Sham, Curcumin-treated Sham (Sham+Cur), bile duct ligation (BDL), Curcumin-treated BDL (BDL+Cur)). * P value<0·05 compared with the Sham group. † P value<0·05 compared with the BDL group.

Figure 7

Fig. 4 The beneficial effect of curcumin against bile duct ligation (BDL)-induced liver fibrosis and hepatic insulin resistance is presented. This schematic diagram shows the effect of curcumin on intracellular molecules involved in these two pathological states in rats. JAK2, Janus kinase 2; STAT3, signal transducer and activator of transcription 3; NOX1, dinucleotide phosphate oxidase 1; RAc1, Ras-related C3 botulinum toxin substrate 1; ROS, reactive oxygen species; ERK1, extracellular signal-regulated kinase 1; SOCS3, suppressor of cytokine signalling 3; HIF-1, hypoxia-inducible factor-1; Sp1, specific protein 1; IRS1, insulin receptor substrate 1; TGF-1β, transforming growth factor-1β; →, induction or activation, ⊣, inhibition or blockade; or indicates the effect of curcumin on protein/gene expression.